KCKarmela Kim Chan

Karmela Kim Chan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karmela Kim Chan has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Arthroplasty Joint Histology and Surgical Outcomes in Patients on Immune Checkpoint Inhibitors: A Single-Center Case Series

    by Karmela K. Chan, Nilasha Ghosh, Carlos Aude, Edward DiCarlo, Anne R. Bass

    Plain Language Summary This is a case series of 16 patients with cancer who were treated with immune checkpoint inhibitor (ICI) therapy and who underwent 23 joint replacements. Some of these patients were known to have inflammatory arthritis (joint inflammation) as a side effect of the ICI therapy, whereas others were thought to have worsening of established osteoarthritis (OA). We wanted to know whether the patients with OA had ICI-related joint inflammation that was simply not recognized before surgery. We also wanted to know whether patients who undergo joint replacements on ICI have more surgery complications than other people. What we found was that the people who were diagnosed with OA prior to surgery had OA on joint histology. Only the patients with known inflammatory arthritis from ICI had significant inflammation on joint histology. One patient required a revision of her hip joint replacement 3.7 years after surgery (while still on ICI) due to an inflammatory reaction to her joint replacement. We could not determine whether ICI played a role in that complication.


  • Necrotizing and Nonnecrotizing Granulomatous Reactions in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Literature Review

    by Elizabeth Y. Wang, Genna Braverman, Nilasha Ghosh, Deanna P. Jannat-Khah, Karmela K. Chan, Jean-Marie Michot, Bridget Jivanelli, Anne R. Bass

    Objective: Immune checkpoint inhibitors (ICI) have improved cancer outcomes but often cause immune-related adverse events, including granulomatous reactions (GRs). We analyzed GRs in patients receiving anticytotoxic T-lymphocyte–associated protein 4 (anti-CTLA4), antiprogrammed cell death protein 1 (anti-PD1)/antiprogrammed death ligand 1 (anti-PDL1), and anti-CTLA4/anti-PD1 therapies. Methods: We performed a literature review of GRs in patients receiving ICI. Data were extracted from 166 articles, including demographics, GR organ distribution, and pathological findings. Results: In 261 patients, the mean age of GR onset was 59.3 (SD 13.0) years. The most common cancer types were melanoma (57%) and lung cancer (21%). Lymph nodes (52%) and skin (35%) were the predominantly affected organs; however, GRs also involved the liver, kidney, and bone. Granulomas were nonnecrotizing in 64% of cases and necrotizing in 15% of cases. Forty-five percent of patients were treated with systemic corticosteroids (CS), and 11% required a CS-sparing agent. Median follow-up time was 10.1 (IQR 4.0-22.2) months. Most GRs (64%) had resolved by last follow-up. Compared to those treated with combination ICI, patients treated with anti-PD1/anti-PDL1 monotherapy were older and had a longer time to onset of GR. They were less likely to be treated with CS for GRs. In patients with melanoma, necrotizing GRs were more common with combination ICI. GRs in the lungs and lymph nodes were more likely to be nonnecrotizing, and GRs in the liver were more commonly necrotizing. Conclusion: GRs in patients with cancer treated with ICI can occur in many organ systems and were most commonly nonnecrotizing. Patients treated with combination ICI had more severe reactions. Most GRs resolved with CS treatment or ICI discontinuation. (PROSPERO ID: CRD42024501205)


  • Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study

    by Anne R Bass, Fenglong Xie, Deanna Jannat-Khah, Nilasha Ghosh, Karmela K Chan, Ashish Saxena, Jeffrey R Curtis

    Immune checkpoint inhibitor (ICI) associated inflammatory arthritis (ICI-IA) occurs in 4–6% of ICI-treated patients based on one observational study. We identified cases of ICI-IA using administrative claims to study its incidence and characteristics at the population level. We used the Medicare 5% sample to identify patients initiating ICIs. Cancer patients were identified by having ≥ 2 ICD-9/10-CM diagnosis codes from an oncologist for lung cancer, melanoma, or renal/urothelial cancer. ICI-IA was defined as having two Medicare claims ≥ 30 days apart with combinations of ICD-9/10-CM diagnosis codes that favored specificity. ICI-IA was identified in patients with a musculoskeletal diagnosis after ICI initiation, who had i.) no inflammatory arthritis or inflammatory rheumatic disease before ICI initiation ever, and ii) no musculoskeletal complaint in the one year prior to ICI. We examined DMARD utilization and visits to rheumatology in patients with ICI-IA. Landmark analysis and a time varying Cox proportional hazards model for overall survival was constructed. The incidence of ICI-IA was 7.2 (6.1–8.4) per 100 patient years. Patients with ICI-IA were mean (SD) age 73.5(7.0) years, 48% women, 91% white. Median(IQR) time from ICI initiation to first ICI-IA diagnosis was 124(56, 252) days. Only 24(16%) received care from a rheumatologist, and 24(16%) were prescribed a DMARD (46% by a rheumatologist). The HR for mortality in patients with ICI-IA was 0.86 (95% CI 0.59–1.26, p= 0.45). The incidence of ICI-IA identified in claims data is similar to that reported in observational studies, however, few patients are treated with a DMARD or see a rheumatologist. There was no difference in overall survival between ICI-treated patients with and without ICI-IA.


  • Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab

    by Robert Stuver, Santosha A. Vardhana, Akshay Bedmutha, Karmela Kim Chan, Rosna Mirtcheva-Trocheva, Anton Nosov, Heiko Schöder, Alison Moskowitz


  • Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis

    by Runci Wang, Anvita Singaraju, Kathryne E. Marks, Lorien Shakib, Garrett Dunlap, Ifeoluwakiisi Adejoorin, Stinne R. Greisen, Lin Chen, Aidan K. Tirpack, Carlos Aude, et al.

    Immune checkpoint inhibitor (ICI) therapies used to treat cancer, such as anti–PD-1 antibodies, can induce autoimmune conditions in some individuals. The T cell mechanisms mediating such iatrogenic autoimmunity and their overlap with spontaneous autoimmune diseases remain unclear. Here, we compared T cells from the joints of 20 patients with an inflammatory arthritis induced by ICI therapy (ICI-arthritis) with two archetypal autoimmune arthritides, rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Single-cell transcriptomic and antigen receptor repertoire analyses highlighted clonal expansion of an activated effector CD8 T cell population in the joints and blood of patients with ICI-arthritis. These cells were identified as CD38 hi CD127 − CD8 T cells and were uniquely enriched in ICI-arthritis joints compared with RA and PsA and also displayed an elevated interferon signature. In vitro, type I interferon induced CD8 T cells to acquire the ICI-associated CD38 hi phenotype and enhanced cytotoxic function. In a cohort of patients with advanced melanoma, ICI therapy markedly expanded circulating CD38 hi CD127 − T cells, which were frequently bound by the therapeutic anti–PD-1 drug. In patients with ICI-arthritis, drug-bound CD8 T cells in circulation showed marked clonal overlap with drug-bound CD8 T cells from synovial fluid. These results suggest that ICI therapy directly targets CD8 T cells in patients who develop ICI-arthritis and induces an autoimmune pathology that is distinct from prototypical spontaneous autoimmune arthritides.


  • Top Cited Papers

    2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis

    by Bryant R. England, Benjamin J. Smith, Nancy A. Baker, Jennifer L. Barton, Carol A. Oatis, Gordon Guyatt, Allen Anandarajah, Kristine Carandang, Karmela Kim Chan, Deb Constien, et al.

    Objective: To develop initial American College of Rheumatology (ACR) guidelines on the use of exercise, rehabilitation, diet, and additional interventions in conjunction with disease‐modifying antirheumatic drugs (DMARDs) as part of an integrative management approach for people with rheumatoid arthritis (RA).Methods: An interprofessional guideline development group constructed clinically relevant Population, Intervention, Comparator, and Outcome (PICO) questions. A literature review team then completed a systematic literature review and applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to rate the certainty of evidence. An interprofessional Voting Panel (n = 20 participants) that included 3 individuals with RA achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.Results: The Voting Panel achieved consensus on 28 recommendations for the use of integrative interventions in conjunction with DMARDs for the management of RA. Consistent engagement in exercise received a strong recommendation. Of 27 conditional recommendations, 4 pertained to exercise, 13 to rehabilitation, 3 to diet, and 7 to additional integrative interventions. These recommendations are specific to RA management, recognizing that other medical indications and general health benefits may exist for many of these interventions.Conclusion: This guideline provides initial ACR recommendations on integrative interventions for the management of RA to accompany DMARD treatments. The broad range of interventions included in these recommendations illustrates the importance of an interprofessional, team‐based approach to RA management. The conditional nature of most recommendations requires clinicians to engage persons with RA in shared decision‐making when applying these recommendations.


  • Top Cited Papers
    Open Access

    2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis

    by Bryant R. England, Benjamin J. Smith, Nancy A. Baker, Jennifer L. Barton, Carol A. Oatis, Gordon Guyatt, Allen Anandarajah, Kristine Carandang, Karmela Kim Chan, Deb Constien, et al.

    Objective: To develop initial American College of Rheumatology (ACR) guidelines on the use of exercise, rehabilitation, diet, and additional interventions in conjunction with disease‐modifying antirheumatic drugs (DMARDs) as part of an integrative management approach for people with rheumatoid arthritis (RA).Methods: An interprofessional guideline development group constructed clinically relevant Population, Intervention, Comparator, and Outcome (PICO) questions. A literature review team then completed a systematic literature review and applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to rate the certainty of evidence. An interprofessional Voting Panel (n = 20 participants) that included 3 individuals with RA achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.Results: The Voting Panel achieved consensus on 28 recommendations for the use of integrative interventions in conjunction with DMARDs for the management of RA. Consistent engagement in exercise received a strong recommendation. Of 27 conditional recommendations, 4 pertained to exercise, 13 to rehabilitation, 3 to diet, and 7 to additional integrative interventions. These recommendations are specific to RA management, recognizing that other medical indications and general health benefits may exist for many of these interventions.Conclusion: This guideline provides initial ACR recommendations on integrative interventions for the management of RA to accompany DMARD treatments. The broad range of interventions included in these recommendations illustrates the importance of an interprofessional, team‐based approach to RA management. The conditional nature of most recommendations requires clinicians to engage persons with RA in shared decision‐making when applying these recommendations.


  • Top Cited Papers

    Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

    by Anne R Bass, Noha Abdel-Wahab, Pankti D Reid, Jeffrey A Sparks, Cassandra Calabrese, Deanna P Jannat-Khah, Nilasha Ghosh, Divya Rajesh, Carlos Andres Aude, Lydia Gedmintas, et al.

    Objectives To compare the safety and effectiveness of biologic and conventional disease-modifying antirheumatic drugs (DMARDs) for immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA). Methods The retrospective multicentre observational study included patients with a diagnosis of ICI-IA treated with a tumour necrosis factor inhibitor (TNFi), interleukin-6 receptor inhibitor (IL6Ri) and/or methotrexate (MTX); patients with pre-existing autoimmune disease were excluded. The primary outcome was time to cancer progression from ICI initiation; the secondary outcome was time to arthritis control from DMARD initiation. Cox proportional hazard models were used to compare medication groups, adjusting for confounders. Results 147 patients were included (mean age 60.3 (SD 11.9) years, 66 (45%) women). ICI-IA treatment was TNFi in 33 (22%), IL6Ri 42 (29%) and MTX 72 (49%). After adjustment for time from ICI initiation to DMARD initiation, time to cancer progression was significantly shorter for TNFi compared with MTX (HR 3.27 (95% CI 1.21 to 8.84, p=0.019)) while the result for IL6Ri was HR 2.37 (95% CI 0.94 to 5.98, p=0.055). Time to arthritis control was faster for TNFi compared with MTX (HR 1.91 (95% CI 1.06 to 3.45, p=0.032)) while the result for IL6Ri was HR 1.66 (95% CI 0.93 to 2.97, p=0.089). A subset analysis in patients with melanoma gave similar results for both cancer progression and arthritis control. Conclusion The treatment of ICI-IA with a biologic DMARD is associated with more rapid arthritis control than with MTX, but may be associated with a shorter time to cancer progression.


  • A “Gold Standard” in the Management of Arthritis

    by Karmela Kim Chan, Karmela Kim

    Hand radiographs show gold thread used as part of acupuncture treatment for arthritis.